Drugs / EHT102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07288580 | Apr 2026 → Jun 2028 expected | autosomal recessive nonsyndromic hearing loss 9 | Shanghai Euhearing Therapeutics Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EHT102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288580 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “EHT102 injection is a dual-vector gene therapy product developed for the treatment of OTOF-related hearing loss.” NCT07288580 ↗ |